Heterogeneity of the resistance to gefitinib treatment in a non‐small cell lung cancer patient with active epidermal growth factor receptor mutation

Por Xu, Chong‐Rui, Zhong, Wen‐Zhao, Zhou, Qing, Zhang, Xu‐Chao, Yang, Jin‐Ji, Wu, Yi‐Long
Publicado no Thorac Cancer (2016)

Principles of biopsy in suspected lung cancer: priority still based on invasion in the era of targeted therapy?

Por Chen, Hua-Jun, Yang, Jin-Ji, Xu, Chong-Rui, Lei, Yuan-Yuan, Luo, Dong-Lan, Yan, Hong-Hong, Wu, Yi-Long
Publicado em 2013

EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China

Por Pi, Can, Xu, Chong‐Rui, Zhang, Ming‐feng, Peng, Xiao‐xiao, Wei, Xue‐wu, Gao, Xing, Yan, Hong‐Hong, Zhou, Qing
Publicado no Thorac Cancer (2018)

Feasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer

Por Chen, Hua-Jun, Yang, Jin-Ji, Fang, Liang-Yi, Huang, Min-Min, Yan, Hong-Hong, Zhang, Xu-Chao, Xu, Chong-Rui, Wu, Yi-Long
Publicado no Thorac Cancer (2014)

Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial

Por Yang, Jin-ji, Zhou, Qing, Liao, Ri-qiang, Huang, Yi-sheng, Xu, Chong-rui, Wang, Zhen, Wang, Bin-chao, Chen, Hua-jun, Wu, Yi-long
Publicado em 2012

Familial association of lung cancer with liver cancer in first-degree relatives

Por Xu, Chong-Rui, Lin, Huan, Su, Jian, Zhang, Xu-Chao, Huang, Yi-Sheng, Yang, Xue-Ning, Zhou, Qing, Yang, Jin-Ji, Zhong, Wen-Zhao, Wu, Yi-Long
Publicado no Cancer Manag Res (2019)

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-L...

Por Wu, Yi-Long, Xu, Chong-Rui, Hu, Cheng-Ping, Feng, Jifeng, Lu, Shun, Huang, Yunchao, Li, Wei, Hou, Mei, Shi, Jian Hua, Märten, Angela, Fan, Jean, Peil, Barbara, Zhou, Caicun
Publicado no Onco Targets Ther (2018)

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Por Zhou, Qing, Yang, Jin-Ji, Chen, Zhi-Hong, Zhang, Xu-Chao, Yan, Hong-Hong, Xu, Chong-Rui, Su, Jian, Chen, Hua-Jun, Tu, Hai-Yan, Zhong, Wen-Zhao, Yang, Xue-Ning, Wu, Yi-Long
Publicado no J Hematol Oncol (2016)

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Por Dong, Zhong-Yi, Zhang, Jia-Tao, Liu, Si-Yang, Su, Jian, Zhang, Chao, Xie, Zhi, Zhou, Qing, Tu, Hai-Yan, Xu, Chong-Rui, Yan, Li-Xu, Li, Yu-Fa, Zhong, Wen-Zhao, Wu, Yi-Long
Publicado no Oncoimmunology (2017)

Lung Cancer Treatment Disparities in China: A Question in Need of an Answer

Por Yang, Lu-Lu, Zhang, Xu-Chao, Yang, Xue-Ning, Yang, Jin-Ji, Wang, Zhen, Chen, Hua-Jun, Yan, Hong-Hong, Xu, Chong-Rui, Guan, Ji-Lin, He, Yan-Yan, Zhong, Wen-Zhao, An, She-Juan, Wu, Yi-Long
Publicado em 2014

Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study

Por Dong, Song, Zhao, Ning, Deng, Wei, Sun, Hui-wen, Niu, Fei-yu, Yang, Jin-ji, Zhong, Wen-zhao, Li, Feng, Yan, Hong-hong, Xu, Chong-rui, Zhang, Qiu-yi, Yang, Xue-ning, Liao, Ri-qiang, Nie, Qiang, Wu, Yi-long
Publicado no World J Surg Oncol (2017)

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer

Por Gou, Lan-Ying, Li, An-Na, Yang, Jin-Ji, Zhang, Xu-Chao, Su, Jian, Yan, Hong-Hong, Xie, Zhi, Lou, Na-Na, Liu, Si-Yang, Dong, Zhong-Yi, Gao, Hong-Fei, Zhou, Qing, Zhong, Wen-Zhao, Xu, Chong-Rui, Wu, Yi-Long
Publicado no Oncotarget (2016)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

Por Sun, Hao, Liu, Si-Yang, Zhou, Jia-Ying, Xu, Jin-Tian, Zhang, Huang-Kai, Yan, Hong-Hong, Huan, Jiao-Jiao, Dai, Ping-Ping, Xu, Chong-Rui, Su, Jian, Guan, Yan-Fang, Yi, Xin, Yu, Rong-Shan, Zhong, Wen-Zhao, Wu, Yi-Long
Publicado no EBioMedicine (2020)

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer

Por Kang, Jin, Zhang, Xu-Chao, Chen, Hua-Jun, Zhong, Wen-Zhao, Xu, Yang, Su, Jian, Zhou, Qing, Tu, Hai-Yan, Wang, Zhen, Xu, Chong-Rui, Yang, Xue-Ning, Chen, Zhi-Hong, Wu, Xue, Zhang, Xian, Shao, Yang, Wu, Yi-Long, Yang, Jin-Ji
Publicado no Front Oncol (2020)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations

Por Lou, Na-Na, Zhang, Xu-Chao, Chen, Hua-Jun, Zhou, Qing, Yan, Li-Xu, Xie, Zhi, Su, Jian, Chen, Zhi-Hong, Tu, Hai-Yan, Yan, Hong-Hong, Wang, Zhen, Xu, Chong-Rui, Jiang, Ben-Yuan, Wang, Bin-Chao, Bai, Xiao-Yan, Zhong, Wen-Zhao, Wu, Yi-Long, Yang, Jin-Ji
Publicado no Oncotarget (2016)

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I...

Por Zhang, Yi-Chen, Chen, Zhi-Hong, Zhang, Xu-Chao, Xu, Chong-Rui, Yan, Hong-Hong, Xie, Zhi, Chuai, Shao-Kun, Ye, Jun-Yi, Han-Zhang, Han, Zhang, Zhou, Bai, Xiao-Yan, Su, Jian, Gan, Bin, Yang, Jin-Ji, Li, Wen-Feng, Tang, Wei, Luo, Feng Roger, Xu, Xiao, Wu, Yi-Long, Zhou, Qing
Publicado no EBioMedicine (2019)